Aspire Biopharma Holdings (ASBP) Net Equity Issued and Repurchased (2024 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Net Equity Issued and Repurchased came in at $9.0 million in Q2 2026, up 0.55% quarter-over-quarter from $9.0 million in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Net Equity Issued and Repurchased for 2 consecutive years, with $9.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $9.0 million in Q2 2026; TTM through Jun 2026 was $18.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $2.5 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased was $9.0 million for Q2 2026 at Aspire Biopharma Holdings, up from $9.0 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $9.0 million in Q2 2026 and troughed at $28561.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | 9.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.00 Mn |
| Mar 31, 2026 | 8.95 Mn |
| Jun 30, 2024 | 28,561.00 |
| Mar 31, 2024 | 229,084.00 |